Harmony Biosciences Holdings: Pay

Harmony Biosciences Holdings paid its 6 named executives $21.4M in total in FY2025 (Dec). CEO Jeffrey Dayno was paid $7.9M of that.

Pay$100 in the stock at the end of FY22 → $68
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Jeffrey DaynoPresident and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Adam ZaeskeEVP and Chief Commercial Officer
FY2025 (Dec)
1 year
Sandip KapadiaEVP and Chief Financial Officer and Chief Administrative Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Jeffrey DierksFormer EVP and Chief Commercial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2022 (Dec)Not disclosed
3 years
Kumar BudurEVP and Chief Medical & Scientific Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Andrew SerafinEVP, Chief Strategy Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 3 peers with pay on file was $7.9M. The CEO of Harmony Biosciences Holdings was paid $7.9M, about the same as the median.

  1. 1PTC
  2. 2Alkermes plc.
  3. 3Harmony Biosciences Holdings
  4. 4Neurocrine Biosciences
  5. 5AcadiaNot disclosed
  6. 6AvadelNot disclosed
  7. 7AxsomeNot disclosed
  8. 8Catalyst PharmaNot disclosed
  9. 9Intra-CellularNot disclosed
  10. 10IonisNot disclosed
  11. 11Jazz PharmaceuticalsNot disclosed
  12. 12MarinusNot disclosed
  13. 13Sage TherapeuticsNot disclosed
  14. 14SupernusNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.